Aerotime Micro Precision Medical Technology (Shanghai) Co., Ltd. ("Aerotime Micro Precision"), a company deeply engaged in super-micro and high-precision surgical robots, recently announced the completion of hundreds of millions of RMB in Series B financing.
This round saw participation from industrial capital and well-known investment institutions, with follow-on investment from Jinyi Hulian, a subsidiary of Index Ventures. Springwood Capital acted as the exclusive financial advisor. The raised funds will primarily be used to consolidate the technological advantages of core products, complete the ecosystem for the microsurgical robot product series, accelerate clinical registration processes, and promote international market expansion.
Founded in 2022, Aerotime Micro Precision is the world's first innovative enterprise focusing on a platform for small-scale refinement surgical robots. The company's predecessor provided high-precision intelligent device R&D and production services for several internationally renowned medical device companies, accumulating over a decade of profound technical expertise in the field of precision medical device manufacturing. In collaboration with R&D centers in the US and Japan, Aerotime Micro Precision has independently developed underlying components, servo systems, transmission mechanisms, and consumable components for surgical robots, breaking through the bottleneck of relying on imported key technologies. Furthermore, the company has established in-depth cooperation with numerous domestic and international universities and research institutions to jointly advance engineering component and system development, forming a complete innovation chain from underlying technology to clinical application.
Aerotime Micro Precision focuses on the R&D of high-precision platform-based surgical robots. Its product line covers general-purpose microsurgical robots, ophthalmic surgical robots, and related innovative consumables for multi-department robots. Its core technological breakthrough lies in achieving sub-micron single-step motion precision and entirely tremor-free operation, equipped with a 7-degree-of-freedom wrist-style joint design that adapts to the demanding operational requirements in confined surgical spaces. These product innovations are already leading global surgical robot technology and have gained widespread recognition from clinicians in several top-tier hospitals. Collaborations have been established with prestigious medical institutions such as Shanghai Ninth People's Hospital, Ningbo Sixth People's Hospital, and Peking University School of Stomatology to jointly promote the implementation and optimization of surgical robots in clinical settings.
Human eye tissue is extremely fragile, and the surgical space is very confined. Traditional ophthalmic surgery is limited by challenges such as physiological hand tremor (the inherent human hand tremor is about 100 microns), limitations of visual field magnification, and fatigue errors, making it difficult to achieve more stable and precise breakthroughs.
The ophthalmic surgical robot independently developed by Aerotime Micro Precision is a high-precision solution precisely targeting these clinical pain points. It integrates high-precision control algorithms and flexible micro-mechanisms, enabling sub-micron single-step motion and effectively filtering out physiological hand tremors. This helps surgeons breakthrough physiological limits, meets the operational requirements of high-precision fundus surgery, shortens the surgeon's learning curve, transcends the upper limit of the surgeon's ability, and improves surgical success rates.
It is reported that Aerotime Micro Precision's ophthalmic surgical robot has recently completed registration clinical trials, formally entering the critical stage for registration and market launch.
Beyond ophthalmology, Aerotime Micro Precision has also made rapid breakthroughs in the field of microsurgical robots. According to public reports, the company's microsurgical robot 'Kai' already covers multiple fields including reconstructive surgery, maxillofacial surgery, hand surgery, and reconstructive surgery, demonstrating powerful platform extensibility and versatility.
This microsurgical robot features multiple degrees of freedom and a compact size, allowing for rapid deployment in operating rooms. Its front end can be equipped with instruments including the world's smallest forceps, with a diameter of only 2 millimeters and seven degrees of freedom, enabling high-precision anastomosis of blood vessels and lymphatic vessels below 0.3 millimeters and maintaining sub-millimeter consistency over long-duration operations. It possesses high-definition 3D stereoscopic vision, capable of identifying fine structures and tension changes. The lightweight body design facilitates positioning, allowing flexible access to deep head and neck areas, areas around small joints, and other restricted surgical fields, while also supporting integrated deployment across multiple departments and teaching applications.
The Aerotime Micro Precision microsurgical robot has been validated in several clinical practices:
· In June 2025, it assisted the Microsurgery Center of Shanghai Ninth People's Hospital in completing the world's first robot-assisted resection of a giant dermatofibrosarcoma protuberans.
· In July 2025, it was successfully applied at Ningbo Sixth People's Hospital in Zhejiang Province's first domestic microsurgical robot-assisted super-thin perforator flap transplantation.
· In July 2025, it successfully completed superficial temporal artery and posterior auricular vein fine anastomosis at Shanghai Ninth People's Hospital, applied for complex scalp scar repair.
· In September 2025, it supported Peking University School of Stomatology in completing China's first microsurgical robot-assisted vascularized free flap reconstruction surgery in the maxillofacial region.
These cases demonstrate that the robot exhibits good feasibility and stability in various clinical scenarios, suggesting its potential not only as specialized equipment but also as a general-purpose surgical platform covering multiple disciplines and procedures, promoting the universal of complex surgeries. Currently, this equipment is still in the clinical validation stage, and the company plans to further expand the range of indications and continuously optimize system performance through cooperation with authoritative medical institutions.
Over the past decade, China's surgical robot industry has evolved from the first stage represented by laparoscopy and orthopedics to the expansion into emerging directions like intervention and natural orifice surgery. As the market matures, refinement, platformization, and multi-disciplinary expansion are becoming the focus of the new round of competition.
Against this backdrop, Aerotime Micro Precision has chosen the higher-barrier but clinically urgent fields of ophthalmology and microsurgery. This not only cut in a differentiated track but also holds the possibility of amplifying the advantages of platform technology. Its accumulated independent R&D in core components, control algorithms, force feedback, and microsurgical operating systems lays a technological foundation for subsequent multi-field expansion.
Surgical robots have entered a stage of refined development. Future opportunities lie not only in large-scale application but more importantly in solving clinical "pain point surgeries." Aerotime Micro Precision's accelerated layout in clinical implementation and procedure expansion is expected to drive breakthroughs in the high-precision surgical robot industry.
Regarding the successful acquisition of this round of financing, the founder of Aerotime Micro Precision stated: "Our successful Series B financing is, first and foremost, an affirmation from investors of our flawless success record with the first two surgical robots performing surgeries. It also reflects their full confidence in our subsequent efforts to further expand the procedures in this field and enter the commercial market. Furthermore, it injects powerful momentum for our next step into the field of neurosurgery!"
Springwood Capital stated: "Aerotime Micro Precision firmly chooses the difficult yet right path,dedicated to in-depth cultivation in the high-value surgical robot field throughout the long technological journey. The team has not only achieved a high degree of technological autonomy and leadership but is also accelerating breakthroughs in clinical implementation and global expansion. Its products redefine surgical accessibility and precision, providing revolutionary solutions for global doctors and patients. We believe that Aerotime Micro Precision, moving from 'seeing a glimmer of light' to 'creating the dawn' with its long-termism and pursuit of excellence, will inevitably lead industry transformation. We look forward to their continuous deep cultivation, daily refinement, and ultimate achievement of excellence!"
Zheng Li, CEO of Jinyi Hulian, stated: "Jinyi Hulian Investment firmly believes that surgical robots can bring tremendous benefits to human healthcare and has been seeking partners. Simultaneously, we recognize that realizing the practical utility of high-precision surgical robots, benefiting patients and doctors, is a very high-threshold and challenging task. Upon seeing Aerotime Micro Precision's long-term, high-level accumulated dataset, the team's efficient and low-cost modeling capabilities, the high recognition from the market and hospital doctors, and the team's resilience and breakthrough capabilities in organizational pathology, we were impressed. We firmly optimistic the company's future value and anticipate the company, using the pathological gold standard as an entry point, will create the best surgical robot products for global users, bring Aerotime Micro Precision to every hospital worldwide, and benefit everyone across the globe."
